language |
eng
|
Author |
Li Shaolan
Department of Diabetology & Endocrinology, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan
Fan Yang
Department of Diabetology & Endocrinology, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan
Kumagai, Asako
Department of Diabetology & Endocrinology, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan
Kawakita, Emi
Department of Diabetology & Endocrinology, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan
Kitada, Munehiro
1 Department of Diabetology & Endocrinology, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan 2 Division of Anticipatory Molecular Food Science and Technology, Medical Research Institute, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan
Koya, Daisuke
1 Department of Diabetology & Endocrinology, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan 2 Division of Anticipatory Molecular Food Science and Technology, Medical Research Institute, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan
|
Subject | DPP-4; EMT; chemoresistance; ABC transporters; apoptosis; breast cancer
|
Journal Title |
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
|
Volume | 21
|
Issue | 3
|
ISSN(Online) | 1422-0067
|
Published Date | 2020-02
|
DOI | |
PubMed ID | |
Publisher | MDPI
|
NII Type |
Journal Article
|
OAI-PMH Set |
Faculty of Medicine
|
Remark | Authors declare there is no conflict interest with this study. This study was partially supported by grants from the Japan Society for the Promotion of Science awarded to KK (19K08738) and DK (16K15472). This study was partially supported by a Grant for Promoted Research awarded to KK (K2018-28) from Kanazawa Medical University. S.L. is supported by foreign scholar grants from Kanazawa Medical University. Boehringer Ingelheim (Japan), MitsubishiTanabe Pharma and Ono Pharmaceutical, Taisho Pharmaceutical, Kyowa-Hakko Kirin contributed to establishing the Division of Anticipatory Molecular Food Science and Technology. KK is under a consultancy agreement with Boehringer Ingelheim.
|